Fig. 1
From: Evasion of immunosurveillance by genomic alterations of PPARγ/RXRα in bladder cancer
Recurrent genomic alterations of RXRA and PPARG in bladder cancer. a Hotspot S427F/Y mutations of RXRA in TCGA muscle-invasive bladder cancer (MIBC) cohort, BGI/Shenzhen bladder cancer cohort and DFCI/MSKCC bladder cancer cohort (n = 534). b Focal amplification of PPARG in TCGA MIBC. c Correlation of copy number (CN) and mRNA expression of PPARG in TCGA MIBC (P < 2.2e−16). Gray dots represent those samples without CN changes (2.30>CN>1.74). d Pathway enrichment analysis of RXRA-S427F/Y and PPARG-high in bladder cancer relative to “normal” RXRA-WT and non-hotspot or PPARG-low. e Distribution of PPARG mRNA expression, PPARG copy number variation (CNV), and RXRA mutations in subtypes (BASE47 luminal/basal) of TCGA bladder cancer (n = 385). Statistical analysis was performed using Fisher’s exact test and P < 0.05 was considered as statistically significant
